A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders.
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Gandotinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 13 Apr 2018 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2019.
- 01 Oct 2017 Results published in the Leukemia Research
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History